Trial reportIntensive care medicine2008
Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors.
Trial report in Intensive care medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00490477 (Polymyxin-B Hemoperfusion Inactivates Circulating Proapoptotic Factors), which is not on this map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Polymyxin-B Hemoperfusion Inactivates Circulating Proapoptotic Factors
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis.Intensive care medicine · 2018Pooled it
- Discovery Pipeline for Acute Kidney Injury: Molecules, Mechanisms, Models, and Targets.Nephron · 2026Review
- Antimicrobial Peptides for Skin Wound Healing.Biomolecules · 2025Review
- Plasma Extracellular Vesicles from Preeclamptic Patients Trigger a Detrimental Crosstalk Between Glomerular Endothelial Cells and Podocytes Involving Endothelin-1.International journal of molecular sciences · 2025Article
- Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- High-volume hemofiltration does not protect human kidney endothelial and tubular epithelial cells from septic plasma-induced injury.Scientific reports · 2024Article
- Article
- Extracorporeal blood purification therapies for sepsis-associated acute kidney injury in critically ill patients: expert opinion from the SIAARTI-SIN joint commission.Journal of nephrology · 2023Article
- Bacterial extracellular vesicles repress the vascular protective factor RNase1 in human lung endothelial cells.Cell communication and signaling : CCS · 2023Article
- Crosstalk between COVID-19 Infection and Kidney Diseases: A Review on the Metabolomic Approaches.Vaccines · 2023Review
- Ceftazidime/Avibactam, Polymyxin or Tigecycline as a Rescue Strategy for the Treatment of Carbapenem-ResistantInfection and drug resistance · 2023Article
- Acute Endotoxemia-Induced Respiratory and Intestinal Dysbiosis.International journal of molecular sciences · 2022Article
- Potential survival benefit and early recovery from organ dysfunction with polymyxin B hemoperfusion: perspectives from a real-world big data analysis and the supporting mechanisms of action.Journal of anesthesia, analgesia and critical care · 2022Review
- Interaction of Lipopolysaccharide-Spiked Blood with Anti-Fouling Polymyxin B-Modified Glass.Materials (Basel, Switzerland) · 2022Article
- Pathophysiology of COVID-19-associated acute kidney injury.Nature reviews. Nephrology · 2021Review
- Up-to-date information on polymyxin B-immobilized fiber column direct hemoperfusion for septic shock.Acute and critical care · 2021Article
- Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock.International journal of molecular sciences · 2021Review
- Treatment of sepsis-induced acute kidney injury in the ICU: the therapeutic targets do not seem to be established yet.Annals of translational medicine · 2019Article
- pH after the first session of direct hemoperfusion with polymyxin B-immobilized fibers predicts mortality in patients with sepsis and septic shock.Clinical and experimental nephrology · 2018Article
- Mechanisms of sepsis-induced immunosuppression and immunological modification therapies for sepsis.Annals of gastroenterological surgery · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo test the hypothesis that extracorporeal therapy with polymyxin B (PMX-B) may prevent Gram-negative sepsis-induced acute renal failure (ARF) by reducing the activity of proapoptotic circulating factors.
settingMedical-Surgical Intensive Care Units. PATIENTS AND
interventionsSixteen patients with Gram-negative sepsis were randomized to receive standard care (Surviving Sepsis Campaign guidelines) or standard care plus extracorporeal therapy with PMX-B. MEASUREMENTS AND
resultsCell viability, apoptosis, polarity, morphogenesis, and epithelial integrity were evaluated in cultured tubular cells and glomerular podocytes incubated with plasma from patients of both groups. Renal function was evaluated as SOFA and RIFLE scores, proteinuria, and tubular enzymes. A significant decrease of plasma-induced proapoptotic activity was observed after PMX-B treatment on cultured renal cells. SOFA and RIFLE scores, proteinuria, and urine tubular enzymes were all significantly reduced after PMX-B treatment. Loss of plasma-induced polarity and permeability of cell cultures was abrogated with the plasma of patients treated with PMX-B. These results were associated to a preserved expression of molecules crucial for tubular and glomerular functional integrity.
conclusionsExtracorporeal therapy with PMX-B reduces the proapoptotic activity of the plasma of septic patients on cultured renal cells. These data confirm the role of apoptosis in the development of sepsis-related ARF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.